An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual surgery required. Today, the company announced early data from animals and ...

Key Takeaways An experimental drug can delay disability progression in advanced multiple sclerosis patientsTolebrutinib ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...